BMY) from a sell rating to a hold rating in a research note released on Monday morning, Marketbeat reports. They currently have $65.50 target price on the biopharmaceutical company’s stock. In other news, SVP Joseph C. Caldarella sold 16,972 shares of ...
Mideast Times · 6 hours ago
Bristol Myers Squibb
Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “buy” rating reissued by investment analysts at Leerink Swann in a note issued to investors on Tuesday, Analyst Ratings reports. Shares of Bristol-Myers Squibb (NYSE:BMY) traded up …
Ticker Report · 1 day ago
Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “buy” rating reiterated by analysts at BMO Capital Markets in a research report issued to clients and investors on Monday, AnalystRatings.Net reports. They currently have a $82.00 price target on the ... · 7/21/2015
More from Bing News
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Trade-Ideas LLC identified Bristol-Myers Squibb Company ( BMY) as a momo ...
The Street · 7/20/2015
Bristol-Myers Squibb‘s (NYSE:BMY) stock has declined by almost 5% following its Q2 2015 earnings despite the company registering strong overall revenue growth of 7%. [1] So why did this happen? It appears that strong topline growth did not translate ...
Trefis · 7/27/2015
Small biotech Exelixis (NASDAQ:EXEL) also reported success in a kidney-cancer trial, driving its embattled stock up 50%. Bristol-Myers' trial, called Checkmate-025, compared Opdivo with everolimus, better known as …
Investors Business Daily · ByAmy Reeves · 7/20/2015
The sell-side is currently bullish on Bristol-Myers stock. Out of the 27 analysts covering the stock, 13 rate it a Buy, 13 suggest a Hold, while only one indicates a Sell. The 12-month average target price set by the … · 7/22/2015
Bristol Myers
Source: Bristol-Myers Squibb Eliquis, which was co-developed by Pfizer ... Don't be too late to the party -- click here for one stock to own when the Web goes dark.
NASDAQ · 7/25/2015
Bristol Myers
Bristol-Myers Squibb Company (NYSE:BMY) [Trend Analysis] released that the European Commission has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral … · 7/17/2015
PPG Industries
Its annual dividend of 2.2% should help long term investors weather any downturns in the stock price (and/or the overall market) that may occur. Given its somewhat overprice state BMY is probably a low buy. However, with the overall market showing signs of ...
Seeking Alpha · ByDavid White · 7/27/2015

Bristol-Myers Squibb

Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-M…
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
Data from: Wikipedia · Freebase